Incidence and Risk Factors of Second Primary

Cancer after the Initial Primary Human

Papillomavirus Related Neoplasms

- 5 Jiayi Shen^{1,2#}, Huaqiang Zhou^{1,2,#}, Jiaqing Liu^{1,2}, Zhonghan Zhang¹, Wenfeng Fang¹, Yunpeng Yang¹,
- 6 Shaodong Hong¹, Yuxiang Ma³, Ting Zhou¹, Yaxiong Zhang¹, Hongyun Zhao¹, Yan Huang^{1,*}, Li Zhang^{1,*}
- 8 Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of
- 9 Oncology in South China, Collaborative Innovation Center for Cancer Medicine;
- ² Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China;
- ³ Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of
- Oncology in South China, Collaborative Innovation Center for Cancer Medicine.
- 13 ** These authors contributed equally to this work.
- 15 Corresponding Author:

4

7

14

20

21

- 16 Yan Huang and Li Zhang
- 17 Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng
- 18 Road East, Guangzhou, Guangdong 510060, China
- 19 Email address: huangyan@sysucc.org.cn; zhangli6@mail.sysu.edu.cn

Abstract

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Background: Human papillomavirus (HPV)-related cancers are nowadays associated with better survival. However, comprehensive studies in second primary cancer (SPC) after the initial primary HPV-related cancer still remain warranted. Therefore, this study was designed to analyse the incidence and risk factors of SPC after HPV-related cancer. **Methods:** We identified 86,790 patients diagnosed with initial primary HPV-related cancer between 1973 and 2010 in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) 9 database. Standardized incidence ratio (SIR) and cumulative incidence were calculated to assess the risk of SPC after HPV-related cancer. Subdistribution hazard regression was also conducted to figure out the risk factors. **Results:** SIR of SPC after HPV-related cancer was 1.60 (95% confidence interval [CI] 1.55-1.65) for male and 1.25 (95% CI 1.22-1.28) for female. SIR of second primary HPV-related cancer (7.39 [95% CI 6.26-8.68] male and 4.35 [95% CI 4.04-4.67] female) was obviously higher than that of second primary HPV-unrelated cancer (1.54 [95% CI 1.49-1.60] male and 1.16 [95% CI 1.13-1.19] female). 5-year cumulative incidence of SPC was 7.22% (95% CI 6.89%-7.55%) for male and 3.72% (95% CI 3.58%-3.88%) for female. Risk factors of SPC included being married and initial primary cancer (IPC) diagnosed at earlier stage for both gender, and IPC diagnosed at older age as well as surgery performed for female only. **Conclusion:** Patients diagnosed with HPV-related cancer are more likely to develop another primary cancer, as compared with the age-specific reference population. Patients with the risk factors claimed in this study are suggested to screen for SPC regularly. According to the

elevation of SIR of HPV-related SPC, it is suggested that part of the HPV-related SPC cases may be caused by the persistent infection of HPV.

Introduction

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

HPV infection is a common viral infection, with its relatively high prevalence (11% in oral cavity, 26.8% for female in genital organs, 14% for female in anus, 45.2% for male in genital organs and 16% for male in anus). ¹⁻⁵ Many types of HPV have been classified as Group 1 carcinogen by the International Agency for Research on Cancer (IARC). HPV is a carcinogen in some cancers, with base of tongue, tonsillar, or opharyngeal, Waldeyer's ring, anal, vulvar, vaginal, cervical and penile cancers included. 6-9 We grouped cancers listed above as HPV-related cancer and the rest as HPV-unrelated cancer. According to the study by de Martel et al., HPV infection is responsible for 4.5% (630,000 new cases per year) of all cancer cases worldwide. The attributable fraction ranges from < 3% to > 20% in different regions. 10 Despite the burden of HPV-related cancer, we have seen the improvement in the prognosis of HPV-related cancer, due to the more advanced treatment and earlier detection. 11-16 Improved survival from the IPC means the elevated risk of SPC.¹⁷ The investigation into SPC after HPV-related cancer is urgent, based on the high prevalence of HPV-related cancer and the improved survival. There have been some reports about incidence of SPC after some of the HPV-related cancers. SIR after oral, oropharyngeal, anal and cervical cancer was 2.82, 2.99, 1.41 and 1.56 respectively. 18-20 However, in the light of the strong carcinogenic effect of HPV, HPV-related cancer should be classified as a whole when considering SPC, to observe whether there will be some special patterns of the occurrence of SPC. Hereby, we aimed to analyse the incidence and risk factors of SPC after initial primary HPV-related cancer.

Materials and Methods

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

SEER program has been collecting demographic and clinical characteristics and follow up of cancer patients in America since 1973, with its registries covering approximately 34.6 percent of the U.S. population currently. In this study, we acquired data from SEER 9, a database in SEER*Stat software version 8.3.5 containing information of cancer patients from 9 different registers. Patient cohort to be observed in this study included those who were diagnosed to have HPV-related cancer as their IPC between 1973 and 2010. IPC was defined as the first record of primary malignant tumor in SEER system. HPV-related cancer included cancer in base of tongue (C01.9), tonsillar cancer (C02.4, C09), oropharyngeal cancer (C10), Waldeyer's ring cancer (C14.2), anal canal cancer (C21), vulvar cancer (C51), vaginal cancer (C52.9), cervical cancer (C53), and penile cancer (C60).⁶⁻⁹ Those diagnosed with HPV-related cancer when aged less than 18 years old were not involved in this study. Records with death certificate or autopsy only were excluded. Finally, 86,790 patients diagnosed with initial primary HPV-related cancer were included. SPC was defined as the second primary malignant tumor records in SEER system diagnosed between January 1973 and December 2015 and with a latency over or equal to 6 months.²¹ The year of 2010 and 2015 were selected as the last years for the diagnosis of initial primary HPV-related cancer and SPC, respectively, to ensure that all patients included were followed up for at least 5 years. SIR of SPC is defined as observed number of SPC cases in the study cohort divided by expected number of cases computed using age-specific rates from a reference population,

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

weighted according to the age structure of the study population.²² The calculation of SIR was done via the MP-SIR session in SEER software. SIR of SPC after the diagnosed of HPV-related cancer and HPV-unrelated cancer were calculated. In this study, death is regarded as the competing event with SPC. Cumulative incidence analysis was completed under the consideration of competing risk. To figure out the risk factors of SPC after the initial primary HPV-related cancer, we conducted the multivariable subdistribution hazard regression, regarding death as the competing event with SPC.²³ Age. race, marital status, TNM stage and surgery were considered to be potential risk factors of SPC. When conducting subdistribution hazard regression, patient cohort merely included those who were diagnosed to have HPV-related cancer as their IPC between 2004 and 2010, for the reason that TNM stage (6th edition) is only available since 2004. Correspondingly, SPC were defined as SPC records in SEER system diagnosed between January 2004 and December 2015. All the results were presented by gender, except when the IPC was genital cancer, to avoid unexpected bias. Both the cumulative incidence analysis and the subdistribution hazard regression were performed using R version 3.5.0 (Institute for Statistics and Mathematics, Vienna, Austria; www.r-project.org). Statistical significance was set at two-sided P < 0.05. **Results** Incidence of SPC The SIR of SPC after HPV-related cancer was 1.60 (95% CI 1.55-1.65) for male and 1.25 (95% CI 1.22-1.28) for female. (Figure 1) Moreover, SIR of second primary HPV-related cancer (7.39 [95% CI 6.26-8.68] male and 4.35 [95% CI 4.04-4.67] female) was obviously

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

higher than that of second primary HPV-unrelated cancer (1.54 [95% CI 1.49-1.60] male and 1.16 [95% CI 1.13-1.19] female). When SPC site was limited to every single HPV-related site, the consistent elevation of SIR was observed. However, notably, for female patients, SIR of SPC in cervix uteri (1.10 [95% CI 0.89-1.34]) was similar to that of SPC in all sites (1.25 [95% CI 1.22-1.28]). There has been insufficient evidence for the role of HPV in several cancers, which were considered as potentially HPV-related cancer in this study, with esophagus, larynx, nose and nasal sinus, lung, colon and rectum, breast, prostate and urinary bladder included. 24-31 We also observed an increase in SIR of SPC among some of the potentially HPV-related sites, with esophagus (4.16 [95% CI 3.49-4.93] male and 2.88 [95% CI 2.34-3.51] female), larynx (3.21 [95% CI 2.59-3.94] male and 3.00 [95% CI 2.31-3.82] female), nose and nasal sinus (4.36 [95% CI 2.39-7.32] for male only), lung and bronchus (2.66 [95% CI 2.48-2.84] male and 2.08 [95% CI 1.98-2.18] female), trachea (8.42 [95% CI 1.74-24.61] male and 6.48 [95% CI 2.11-15.13] female) and urinary bladder (1.96 [95% CI 1.74-2.20 for female only) included. HPV-related head and neck cancer contributed more to the SIR of SPC after HPV-related cancer than HPV-related anogenital cancer. (Table 1) In addition, how SIR was affected by SPC sites when IPC was limited to every single HPV-related cancer was also provided. (Table S1-6) SIR of SPC after HPV-unrelated cancer (0.88 [95% CI 0.88-0.89] male and 1.12 [95% CI 1.11-1.12] female) was lower when compared with that of SPC after HPV-related cancer (1.60 [95% CI 1.55-1.65] male and 1.25 [95% CI 1.22-1.28] female). (Figure 2)

The temporal pattern of SIR was apparent. SIR would be raised, if the IPC was diagnosed in

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

more recent years. (Figure 3) The 1-year, 3-year, 5-year and 10-year cumulative incidence of SPC was 1.19% (95% CI 1.06%-1.33%) for male and 0.63% (95% CI 0.57%-0.69%) for female, 4.78% for male (95% CI 4.51%-5.06%) and 2.33% (95% CI 2.22%-2.45%) for female, 7.22% (95% CI 6.89%-7.55%) for male and 3.72% (95% CI 3.58%-3.88%) for female and 11.98% (95% CI 11.56%-12.42%) for male and 6.87% (95% CI 6.67%-7.08%) for female, respectively. Risk factors of SPC Marital status and TNM stage were significantly associated with SPC for both genders. (Table 2) Age and surgery were also significant predictive factors of SPC for female patients. According to the result of subdistribution hazard regression, older female patient (with their IPC diagnosed when aged over 65 years old) (sdHR=1.50, [95% CI 1.28 - 1.76], P<0.001) were at more risk for SPC. As compared with married patients, those unmarried got a lower risk of developing SPC, with the sdHR of 0.74 (95% CI 0.63 - 0.86, P<0.001) for male and 0.77 (95% CI 0.66 - 0.90, P<0.001) for female, respectively. In this study, those variables related to poor prognosis, including later TNM stage for both gender and surgery not performed for female, were also protective factors for SPC. **Discussion** In this study, we estimated the risk and risk factors of SPC after the initial primary HPV-related cancer. The SIR of SPC was 1.60 (95% CI 1.55-1.65) for male and 1.25 (95% CI

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

1.22-1.28) for female. The SIR, which was larger than 1, indicated that patients diagnosed with HPV-related cancer are more likely to develop another primary cancer, as compared with the age-specific reference population. Patients with the risk factors claimed in the competing risk analysis are suggested to screen for SPC regularly. The elevation of SIR (>1) can partially be explained by their persistent carcinogenic lifestyle like smoking and alcohol consumption. 32, 33 In addition, patients once diagnosed with HPV-related cancer may be also those who were genetically susceptible to cancer, thus being more likely to develop another primary cancer than the corresponding reference population.³⁴ If those two hypotheses mentioned above were the only two explanations of SPC after HPV-related cancer, we would have seen the similar SIR of different SPC sites, because the carcinogenic effect of both the carcinogenic lifestyle and being genetically susceptible to cancer exists in most of cancers. However, we actually observed the elevation of SIR of SPC in HPV-related sites and this result is also supported by Neumann et al. 35 Moreover, considering the strong carcinogenic effect of HPV in the HPV-related sites⁶⁻⁹, it is suggested that part of the HPV-related SPC cases may be caused by the persistent infection of HPV. HPV can be transmitted from the primary infected site to the later infected sites. To be specific, HPV virus can circulate to infect other organs, with HPV DNA and mRNA detected in peripheral blood of cervical cancer patients. 36, 37 Another theory for the transmission of HPV from anus, cervix uteri and other genital organs to oral cavity, oropharynx and tonsil and then causing SPC is that HPV was transmitted in the process of oral sex or by touching the mouth with contaminated hands. Moreover, another primary cancer in the same site as that in IPC may also occur under the effect of HPV, after the elimination of tumor cells of IPC. Next,

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

in those organs infected later, the similar carcinogenic process of HPV with that in IPC occurs. Considering the carcinogenic effect of HPV in both the IPC and its potential carcinogenic effect in second primary HPV-related cancer, HPV vaccine is promoted for the prevention, based on the benefit of HPV vaccination claimed by Nicol et al.³⁸ We observed the elevation of SIR in some of the potentially HPV-related SPC sites including esophagus, larynx, nose and nasal sinus (for male only), lung and bronchus, trachea and urinary bladder (for female only). According to the hypothesis that the infection of HPV may be a reason for the occurrence of SPC, we think this can be an indirect evidence for the carcinogenicity of HPV in these potentially HPV-related sites, of which SIR was elevated. For instance, as was promoted by Xiong WM et al., HPV can be transmitted to and infect lung by blood circulation, through the air or by high-risk sexual behavior, through which HPV was transmitted to mouth, throat and then lung.³⁹ Then, HPV performs its carcinogenicity, causing second primary lung cancer. 36, 37 And this is also an indication for the necessity of further exploration of the carcinogenic effect of HPV in esophagus, larynx, nose and nasal sinus, lung and bronchus, trachea and urinary bladder. The SIR of SPC after HPV-unrelated cancer is lower than 1 for male. But this can not be the evidence of that HPV-unrelated cancer is a protective factor for the development of another primary cancer in male, because there have been many reports of SIR after HPV-unrelated cancers like hepatocellular cancer (10.07), stage Ia non-small-cell lung cancer (2.07), gastric cancer (1.11) and osteosarcoma (1.60), which was significantly larger than 1.21, 40-42 However, this can be an indication that there might be survivors from some specific cancers who may be less likely to develop another primary cancer when compared with the corresponding

population due to the poor prognosis or so on, which needs further investigation. For example, SIR of SPC after the initial primary gastroenteropancreatic neuroendocrine tumors was reported to be 0.72.⁴³ We also saw the increase of SIR by attained calendar year, which means a growing necessity of screening for SPC nowadays. Our results were same to those by Suk et al. 44 We assumed that the possible reason for the increase may be the improvement of survival from many of the HPV-related cancers in recent years and the arising and popularization of the more effective detection approaches. 11-16, 45, 46 The improvement of survival reduced the competing effect of death with SPC, while the more effective detection approach made the detection of some cases possible. According to the result of the subdistribution hazard regression, some prognostic indicators of IPC were also indicators for the occurrence of SPC, with TNM stage (for both gender) and surgery (for female only) included. Further, indicators of better survival of IPC also implied a larger chance of developing SPC, which was supported by the Grundmann et al. 17 There are also some limitations in our study. First of all, although we believe in the quality of records in SEER system, there may be some incorrect records of SPC in SEER, for the natural difficulty in distinguishing SPC from tumor metastasis and recurrence. Second, information about infection of HPV and lifestyle of patients like smoking and alcohol consumption is not available in SEER database. Because of the lack of information about HPV-positivity status, HPV-relatedness was by proxy in this study.

Conclusions

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

This study is of clinical significance and can help promote public health. According to our results, considering the persistent carcinogenesis of HPV and the SIR of SPC increasing by year, patients once diagnosed with HPV-related cancer should screen for SPC regularly, especially when they get a high predictive risk for SPC according to the result of our subdistribution hazard regression.

Acknowledgments

The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in providing high quality open resources for researchers.

The authors would like to thank the editors and the anonymous reviewer for their valuable comments and suggestions to improve the quality of the paper.

References

- 255 1. Candotto V, Lauritano D, Nardone M, et al. HPV infection in the oral cavity: epidemiology, clinical
- manifestations and relationship with oral cancer. Oral Implantol. 2017;10: 209-220.
- 257 2. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United
- 258 States. JAMA. 2007;297: 813-819.
- 259 3. Hernandez BY, McDuffie K, Zhu X, et al. Anal human papillomavirus infection in women and its
- relationship with cervical infection. Cancer Epidemiol. Biomarkers Prev. 2005;14: 2550-2556.
- 261 4. Han JJ, Beltran TH, Song JW, Klaric J, Choi YS. Prevalence of Genital Human Papillomavirus
- 262 Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and
- 263 Nutrition Examination Survey (NHANES) 2013-2014. JAMA Oncol. 2017;3: 810-816.
- 264 5. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Age-specific prevalence of and risk factors for
- 265 anal human papillomavirus (HPV) among men who have sex with women and men who have sex with
- 266 men: the HPV in men (HIM) study. J. Infect. Dis. 2011;203: 49-57.
- 267 6. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus
- prevalence in invasive penile cancer. Cancer Causes Control. 2009;20: 449-457.
- 269 7. Vuyst HD, De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and
- type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina
- and anus: A meta-analysis. International Journal of Cancer. 2009;124: 1626-1636.
- 8. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of
- invasive cervical cancer worldwide. J. Pathol. 1999;189: 12-19.
- 274 9. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human
- papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J. Clin.

- 276 Oncol. 2008;26: 612-619.
- 277 10. Martel Cd, de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer
- attributable to HPV by site, country and HPV type. International Journal of Cancer. 2017;141: 664-670.
- 279 11. Akhtar-Danesh N, Elit L, Lytwyn A. Temporal Trends in the Relative Survival Among Women With
- 280 Cervical Cancer in Canada: A Population-Based Study. International Journal of Gynecologic Cancer.
- 281 **2012;22**: **1208-1213**.
- 282 12. Arya M, Li R, Pegler K, et al. Long-term trends in incidence, survival and mortality of primary penile
- cancer in England. Cancer Causes Control. 2013;24: 2169-2176.
- 13. Chen AY, Zhu J, Fedewa S. Temporal trends in oropharyngeal cancer treatment and survival:
- 285 1998–2009. The Laryngoscope. 2014;124: 131-138.
- 286 14. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and
- survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101:
- 288 **281-288**.
- 289 15. Lai J, Elleray R, Nordin A, et al. Vulval cancer incidence, mortality and survival in England:
- 290 age-related trends. BJOG. 2014;121: 728-738; discussion 739.
- 291 16. Pulte D, Brenner H. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st
- 292 Century: A Period Analysis. The Oncologist. 2010;15: 994-1001.
- 293 17. Grundmann RT, Meyer F. [Second primary malignancy among cancer survivors epidemiology,
- 294 prognosis and clinical relevance]. Zentralbl. Chir. 2012;137: 565-574.
- 295 18. Morris LGT, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head
- 296 and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal
- 297 cancer. J. Clin. Oncol. 2011;29: 739-746.

- 298 19. Shah BK, Budhathoki N. Second primary malignancies in anal carcinoma. Journal of Clinical
- 299 Oncology. 2015;33: 534-534.
- 300 20. Teng C-J, Huon L-K, Hu Y-W, et al. Secondary Primary Malignancy Risk in Patients With Cervical
- 301 Cancer in Taiwan. Medicine. 2015;94: e1803.
- 302 21. Shah BK, Kandel P, Khanal A. Second Primary Malignancies in Hepatocellular Cancer A US
- Population-based Study. Anticancer Res. 2016;36: 3511-3514.
- 304 22. Schoenberg BS, Myers MH. Statistical methods for studying multiple primary malignant neoplasms.
- 305 Cancer. 1977:40: 1892-1898.
- 306 23. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J. Am.
- 307 Stat. Assoc. 1999;94: 496-509.
- 308 24. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck
- 309 squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev.
- 310 **2005**; **14**: **467-475**.
- 311 25. Lu XM, Monnier-Benoit S, Mo LZ, et al. Human papillomavirus in esophageal squamous cell
- carcinoma of the high-risk Kazakh ethnic group in Xinjiang, China. European Journal of Surgical
- 313 Oncology (EJSO). 2008;34: 765-770.
- 314 26. El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing
- 315 (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease
- 316 entity. Am. J. Surg. Pathol. 2005;29: 1367-1372.
- 27. Giuliani L, Favalli C, Syrjanen K, Ciotti M. Human papillomavirus infections in lung cancer.
- Detection of E6 and E7 transcripts and review of the literature. Anticancer Res. 2007;27: 2697-2704.
- 28. Bodaghi S. Colorectal Papillomavirus Infection in Patients with Colorectal Cancer. Clinical Cancer

- 320 Research. 2005;11: 2862-2867.
- 321 29. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE. High-risk human
- 322 papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a
- 323 tissue microarray study. Br. J. Cancer. 2008;99: 404-407.
- 324 30. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K. Detection of human
- papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina.
- 326 BMC Urology. 2005;5.
- 327 31. Barghi MR, Hajimohammadmehdiarbab A, Moghaddam SH, Kazemi B. Correlation between human
- 328 papillomavirus infection and bladder transitional cell carcinoma. BMC Infectious Diseases. 2005;5.
- 329 32. Vineis P, Alavanja M, Buffler P, et al. Tobacco and Cancer: Recent Epidemiological Evidence. JNCI
- Journal of the National Cancer Institute. 2004;96: 99-106.
- 33. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006;7: 149-156.
- 332 34. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the
- role of polymorphisms in candidate genes. JAMA. 2008;299: 2423-2436.
- 334 35. Neumann F, Jégu J, Mougin C, et al. Risk of second primary cancer after a first potentially-human
- papillomavirus-related cancer: A population-based study. Preventive Medicine. 2016;90: 52-58.
- 336 36. Tseng C-J, Pao CC, Lin J-D, Soong Y-K, Hong J-H, Hsueh S. Detection of Human Papillomavirus
- 337 Types 16 and 18 mRNA in Peripheral Blood of Advanced Cervical Cancer Patients and Its Association
- With Prognosis. Journal of Clinical Oncology. 1999;17: 1391-1391.
- 339 37. Liu VW, Tsang P, Yip A, Ng TY, Wong LC, Ngan HY. Low incidence of HPV DNA in sera of
- pretreatment cervical cancer patients. Gynecol. Oncol. 2001;82: 269-272.
- 38. Nicol AF, de Andrade CV, Russomano FB, et al. HPV vaccines: their pathology-based discovery,

- benefits, and adverse effects. Ann. Diagn. Pathol. 2015;19: 418-422.
- 343 39. Xiong W-M, Xu Q-P, Li X, Xiao R-D, Cai L, He F. The association between human papillomavirus
- infection and lung cancer: a system review and meta-analysis. Oncotarget. 2017;8: 96419-96432.
- 345 40. Khanal A, Lashari BH, Kruthiventi S, et al. The risk of second primary malignancy in patients with
- stage la non-small cell lung cancer: a U.S. population-based study. Acta Oncologica. 2018;57:
- 347 **239-243**.
- 348 41. Shah BK, Khanal A, Hewett Y. Second Primary Malignancies in Adults with Gastric Cancer A US
- Population-Based Study. Front. Oncol. 2016;6: 82.
- 350 42. Lee JS, DuBois SG, John Boscardin W, Wustrack RL, Goldsby RE. Secondary malignant
- 351 neoplasms among children, adolescents, and young adults with osteosarcoma. Cancer. 2014;120:
- 352 **3987-3993**.
- 43. Kamp K, Damhuis RAM, Feelders RA, de Herder WW. Occurrence of second primary malignancies
- in patients with neuroendocrine tumors of the digestive tract and pancreas. Endocrine-Related Cancer.
- 355 **2012**; **19**: **95**-**99**.

- 44. Suk R, Mahale P, Sonawane K, et al. Trends in Risks for Second Primary Cancers Associated With
- 357 Index Human Papillomavirus-Associated Cancers. JAMA Network Open. 2018;1: e181999.
- 358 45. Hillemanns P, Soergel P, Hertel H, Jentschke M. Epidemiology and Early Detection of Cervical
- 359 Cancer. Oncol Res Treat. 2016;39: 501-506.
- 360 46. Leeds IL. Anal cancer and intraepithelial neoplasia screening: A review. World Journal of
- 361 Gastrointestinal Surgery. 2016;8: 41.

Table 1. SIRs of all site after the diagnosis of HPV-related cancer (initial primary sites shown)

Initial Primary Sita		Male		Female
Initial Primary Site	Observed	SIR(95%CI)	Observed	SIR(95%CI)
HPV-Related Sites	3,463	1.60# (1.55-1.65)	7,372	1.25# (1.22-1.28)
HPV-related Oral Cancer	2,531	1.85# (1.78-1.92)	911	2.25# (2.11-2.40)
Vulva	NA	NA	1,273	1.41# (1.34-1.49)
Vagina	NA	NA	224	1.29# (1.13-1.47)
Anus	454	1.22# (1.11-1.33)	650	1.31# (1.21-1.42)
Penis	478	1.13# (1.03-1.24)	NA	NA
Cervix Uteri	NA	NA	4,314	1.10# (1.07-1.13)

Confidence intervals are 95%.

[#] P<0.05.

^{*} Confidence interval.

 $\hbox{ Table 2. Hazard model of probabilities of SPM after initial primary HPV-related cancer } \\$

	SPM of Ma	le	SPM of Fem	ale
Characteristic	sdHR# (95% Cl*)	p-value	sdHR# (95% Cl*)	p-value
Age				
18-65 years	Reference			
65+ years	1.08 (0.92 - 1.27)	0.360	1.50 (1.28 - 1.76)	<0.001
Race				
White	Reference			
Black	1.04 (0.82 - 1.32)	0.730	1.08 (0.87 - 1.34)	0.470
Other/Unknown	0.74 (0.51 - 1.09)	0.130	0.92 (0.72 - 1.17)	0.480
Marital Status				
Married	Reference			
Unknown	0.77 (0.54 - 1.10)	0.150	0.88 (0.66 - 1.17)	0.390
Unmarried	0.74 (0.63 - 0.86)	<0.001	0.77 (0.66 - 0.90)	<0.001
TNM stage				
L	Reference			
П	0.74 (0.56 - 1.00)	0.049	1.11 (0.90 - 1.36)	0.320
Ш	0.87 (0.67 - 1.15)	0.330	0.84 (0.67 - 1.05)	0.120
IV	0.67 (0.53 - 0.85)	0.001	0.66 (0.50 - 0.86)	0.002
Unknown	0.67 (0.50 - 0.91)	0.009	1.10 (0.88 - 1.37)	0.420
Surgery				
Surgery Performed	Reference			
Surgery not Performed	0.97 (0.83 - 1.13)	0.660	0.73 (0.62 - 0.86)	<0.001

^{*} sdHR: subdistribution hazard ratio; * CI: confidence interval.

Figure legends

- Figure 1. SIRs after the diagnosis of the initial primary HPV-related cancer
- Figure 2. SIRs after the diagnosis of the initial primary HPV-unrelated cancer
- **Figure 3.** SIRs after the diagnosis of the initial primary HPV-related cancer by attained calendar year

SPM Site	Observed Cases	SIR		SPM Site	Observed Cases	SIR	
All Sites	7,372	1.25		All Sites	3,463	1.60	•
All Solid Tumors	6,638	1.26		All Solid Tumors	3,154	1.63	
HPV-Related Cancer	735	4.35	•	HPV-Related Cancer	150	7.39	н
HPV-Unrelated Cancer	6,637	1.16		HPV-Unrelated Cancer	3,313	1.54	
Oral Cavity preprint doi: https://doi.org/10.1101/2020.01.29.190045	07; this version posted January 3, who has granted med (2)	30,2020. Ti en 3a 36 isp	he copyright holder for this preprint play the preprint in perpetuity.	Oral Cavity and pharynx	552	8.25	•
Oral Cancer	reuse allowed without permission 216	on. 3.57	HIII	Oral Cancer	379	9.86	H=1
Tonsil	38	4.09	⊢⊪ 4	Tonsil	43	4.25	⊢
Oropharynx	10	3.89	H -■	Oropharynx	30	12.24	⊢ -
Female Genital System	1,026	1.42	•	Male Genital System	647	0.95	•
Cervix Uteri	97	1.10	•	Prostate	602	0.89	•
Ovary	183	0.95		Penis	38	11.92	⊢ − ⊪ − − 1
Vagina	166	15.12	⊢ -⊪ -1	Respiratory System	987	2.72	•
Vulva	330	9.57	⊢⊪ -1	Nose, Nasal Cavity and Middle Ear	14	4.36	⊢ ⊪ −1
Respiratory System	1,677	2.10	•	Larynx	91	3.21	HEI
Nose, Nasal Cavity and Middle Ear	13	1.72	H=-I	Lung and Bronchus	879	2.66	
Larynx	65	3.00	H=4	Trachea	3	8.42	⊢ -
Lung and Bronchus	1,594	2.08		Digestive System	596	1.39	•
Trachea	5	6.48	⊢- I	Esophagus	136	4.16	HIII
Digestive System	1,478	1.27	•	Stomach	56	1.27	
Esophagus	97	2.88	HEI	Colon and Rectum	227	0.99	•
Stomach	123	1.38	•	Colon excluding Rectum	145	0.91	
Colon and Rectum	814	1.17		Rectum and Rectosigmoid Junction	82	1.19	
Colon excluding Rectum	567	1.07		Anus, Anal Canal and Anorectum	39	8.63	⊢- ■− -I
Rectum and Rectosigmoid Junction	247	1.47		Liver	48	1.42	·
Anus, Anal Canal and Anorectum	94	4.03	H=H	Pancreas	61	1.08	•
Liver	47	1.16		Breast	3	0.66	•
Pancreas	176	1.02		Urinary System	216	0.94	•
Breast	1,340	0.75	•	Urinary Bladder	139	0.91	•
Urinary System	438	1.54	•	Kidney	68	1.05	•
Urinary Bladder	291	1.96	•	Brain	13	0.59	•
Kidney	104	0.91		Thyroid	18	1.23	•
Brain	45	0.79	•	All Lymphatic and Hematopoietic Diseases	228	1.24	•
Thyroid	96	0.77	•	Lymphoma	132	1.48	•
All Lymphatic and Hematopoietic Diseases	473	1.02	•	Leukemia	68	1.08	•
Lymphoma	268	1.11		Skin excluding Basal and Squamous	94	0.96	•
Leukemia	145	1.04		Melanoma of the Skin	75	0.83	
Skin excluding Basal and Squamous	153	0.78	•				0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 25 SIR
Melanoma of the Skin	132	0.74					
			0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 SIR				

	_	_			
iviale	N	1	a	ı	e

All Sites 158,188 1.12 ■ All Sites 186,579 0.88 ■ All Solid Tumors 141,983 1.13 ■ All Solid Tumors 162,514 0.87 ■ HPV-Related Cancer 2,969 0.87 ■ HPV-Related Cancer 1,744 1.15 ■
HPV-Related Cancer 2,969 0.87 ■ HPV-Related Cancer 1,744 1.15 ■
HPV-Unrelated Cancer 155,219 1.12 • HPV-Unrelated Cancer 184,835 0.88 •
Oral Cavity icanal remarks preprint doi: https://doi.org/10.1101/2020.01.29.19004507; this version posted January 30, 2020. The copyright holder for this preprint Cavity icanal remarks preprint with preprint in perpetuity. Oral Cavity and pharynx 6,930 1.28
Oral Cancer 2,182 1.44 Oral Cancer 4,118 1.29
Tonsil 236 1.22
Oropharynx 77 1.29 ► - □ Oropharynx 217 1.19 ► - □
Female Genital System 14,727 0.92 Male Genital System 31,536 0.49
Cervix Uteri 979 0.68 ■ Prostate 30,535 0.48 ■
Ovary 4,093 0.92 Penis 316 0.94
Vagina 361 1.36 H■→ Respiratory System 38,812 1.07
Vulva 804 0.88 ■ Nose, Nasal Cavity and Middle Ear 373 1.27 ■
Respiratory System 23,785 1.16 ⋅ Larynx 2,652 1.08 ■
Nose, Nasal Cavity and Middle Ear 232 1.25 Lung and Bronchus 35,665 1.07
Larynx 528 1.12 ★ □ Trachea 73 2.25 ★ □ → → → → → → → → → →
Lung and Bronchus 22,952 1.15 • Digestive System 41,915 0.98
Trachea 38 2.10
Digestive System 31,178 1.03 ⋅ Stomach 4,480 0.97
Esophagus 1,088 1.28 • Colon and Rectum 22,678 0.96 •
Stomach 2,382 1.08 ■ Colon excluding Rectum 16,488 0.97 ■
Colon and Rectum 19,121 1.04 Rectum and Rectosigmoid Junction 6,190 0.95
Colon excluding Rectum 15,029 1.05 • Anus, Anal Canal and Anorectum 483 1.31 •
Rectum and Rectosigmoid Junction 4,092 1.00 Liver 2,232 0.81
Anus, Anal Canal and Anorectum 512 0.95 Pancreas 5,539 0.97
Liver 833 0.86 ■ Breast 512 1.13 ◆
Pancreas 4,489 0.97 ■ Urinary System 26,193 1.11 •
Breast
Urinary System
Urinary Bladder 5,080 1.23 ■ Brain •
Kidney 2,917 1.06 ■ Thyroid 1,416 1.35 ◆
Brain 1,267 0.94 ◆ All Lymphatic and Hematopoietic Diseases 19,162 1.04 •
Thyroid
All Lymphatic and Hematopoietic Diseases 12,627 1.06 • Leukemia 6,565 1.00
Lymphoma 6,453 1.04 Skin excluding Basal and Squamous 11,253 1.24 •
Leukemia 4,388 1.17 ■ Melanoma of the Skin 10,093 1.25 ■
Skin excluding Basal and Squamous 6,152 1.39 +
Melanoma of the Skin 5,498 1.39

